Related Experiment Videos
The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates
K W Lange1, P A Löschmann, E Sofic
1Department of Clinical Neurochemistry, University of Würzburg, Germany.
Abstract:
Degeneration of nigrostriatal dopaminergic neurons is the primary histopathological feature of Parkinson's disease. The neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induces a neurological syndrome in man and non-human primates very similar to idiopathic Parkinson's disease by selectively destroying dopaminergic nigrostriatal neurons. This gives rise to the hypothesis that Parkinson's disease may be caused by endogenous or environmental toxins. Endogenous excitatory amino acids (EAAs) such as L-glutamate could be involved in neurodegenerative disorders including Parkinson's disease. We report in this study that the competitive NMDA antagonist CPP (3-((+/-)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid) protects nigral tyrosine hydroxylase (TH) positive neurons from degeneration induced by systemic treatment with MPTP in common marmosets. This indicates that EAAs are involved in the pathophysiological cascade of MPTP-induced neuronal cell death and that EAA antagonists may offer a neuroprotective therapy for Parkinson's disease.
Insights
Parkinson's disease involves the loss of specific neurons. This study shows that blocking excitatory amino acids with CPP protects these neurons from MPTP toxin, suggesting a potential therapy for Parkinson's disease.
Area of Science:
- Neuroscience
- Neuropharmacology
- Toxicology
Background:
- Parkinson's disease is characterized by the degeneration of nigrostriatal dopaminergic neurons.
- The neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) reliably reproduces Parkinson's-like symptoms by destroying these neurons.
- Endogenous excitatory amino acids (EAAs) are implicated in neurodegenerative processes.
Purpose of the Study:
- To investigate the role of EAAs in MPTP-induced neurodegeneration.
- To evaluate the neuroprotective potential of NMDA antagonists in a primate model of Parkinson's disease.
Main Methods:
- Common marmosets were treated systemically with MPTP.
- The neuroprotective effects of the NMDA antagonist CPP (3-((+/-)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid) were assessed.
- Protection of nigral tyrosine hydroxylase (TH) positive neurons was quantified.
Main Results:
- CPP treatment significantly protected nigral TH-positive neurons from MPTP-induced degeneration.
- This demonstrates the involvement of EAAs in the neurotoxic cascade triggered by MPTP.
- The findings support the hypothesis that EAAs contribute to Parkinson's disease pathology.
Conclusions:
- Excitatory amino acids play a critical role in MPTP-induced nigrostriatal dopaminergic neuron death.
- NMDA antagonists, such as CPP, show promise as a neuroprotective therapy for Parkinson's disease.
- Targeting EAA pathways may offer a novel therapeutic strategy for Parkinson's disease.